News

During the exhibition MEDICA 2024, Autobio held a European regional distributor meeting in Düsseldorf, Germany, to which more than 70 customers were invited.

Mr. Fu Guangyu, Executive Vice President of the company, said in his speech that Autobio's products have covered more than 30 countries in Europe and won wide attention and high praise from customers. This year, the company has established a number of overseas subsidiaries to further strengthen the localization strategy. At the same time, the company has actively established a strategic partnership with MBL and IFCC in Japan, and successfully entered the high-end market.Autobio will continue to accelerate the global layout, take advantage of its products and team, and work with many excellent strategic partners to firmly promote the implementation of cooperative projects, build a market community of destiny, and achieve mutual benefit and win-win situation.

At the meeting, Autobio also invited Ms. Cinzia from Italy and Mr. Karolis from Lithuania to share their cases of win-win cooperation with enterprises.

Ms. Cinzia said that the cooperation with Autobio started with the recognition of its innovative strength and product quality, in the course of the cooperation, the two sides jointly committed to provide advanced medical testing products and solutions to the European market, Autobio's professional team, efficient service and continuous product innovation have laid a solid foundation for the cooperation between the two sides.

Mr. Karolis gave an in-depth analysis of the current situation in the Eastern European market, highlighting the growing demand for high-end medical testing products and the challenges posed by increased competition and laws and regulations. He also mentioned that Autobio has laid a solid foundation for its entry into the Eastern European market with the innovation and reliability of its products.

Autobio adheres to the tenet of “Committed to the promotion and advancement of medical laboratory technology, dedicated to serving human healthcare”, emphasizes investment in innovation, enriches our product line, and further expands the international market, so as to make greater contributions to the advancement of global medical care and the health and well-being of human beings.